Publicacións en colaboración con investigadores/as de Corporació Sanitària Parc Taulí (23)

2021

  1. Multicentre, randomised, open-label, phase IV-III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: Study protocol for the SAFO trial

    BMJ Open, Vol. 11, Núm. 8

2020

  1. Association of a single nucleotide polymorphism combination pattern of the Klotho gene with non-cardiovascular death in patients with chronic kidney disease

    Clinical Kidney Journal, Vol. 13, Núm. 6, pp. 1017-1024

2019

  1. Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort

    Frontiers in Genetics, Vol. 10, Núm. FEB

  2. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 7, pp. 2277-2283.e2

2017

  1. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: The NEFRONA study

    Nephrology Dialysis Transplantation, Vol. 32, Núm. 3, pp. 513-520

2015

  1. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease

    Nephrology Dialysis Transplantation, Vol. 30, Núm. 7, pp. 1176-1185

  2. Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial

    BMJ Open, Vol. 5, Núm. 3

2014

  1. Analysis of two autoimmunity genes, IRAK1 and MECP2, in giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 32, Núm. SUPPL.82

  2. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

    Tumori, Vol. 100, Núm. 2, pp. 225-231

2013

  1. A case-control study suggests that the CCR6 locus is not involved in the susceptibility to giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 31, Núm. SUPPL.75

  2. Evidence of association of the NLRP1 gene with giant cell arteritis

    Annals of the Rheumatic Diseases

  3. Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis

    Annals of the Rheumatic Diseases, Vol. 72, Núm. 11, pp. 1882-1886

2012

  1. Autoimmune disease-associated CD226 gene variants are not involved in giant cell arteritis susceptibility in the Spanish population

    Clinical and Experimental Rheumatology, Vol. 30, Núm. SUPPL. 70

  2. Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis

    Journal of Rheumatology, Vol. 39, Núm. 6, pp. 1275-1279

  3. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

  4. The undiagnosed cases of Clostridium difficile infection in a whole nation: Where is the problem?

    Clinical Microbiology and Infection, Vol. 18, Núm. 7

2011

  1. Effects of omalizumab in Aspergillus-associated airway disease

    Thorax

  2. Role of the CCR5/Δ32CCR5 polymorphism in biopsy-proven giant cell arteritis

    Human Immunology, Vol. 72, Núm. 5, pp. 458-461

  3. Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 1 SUPPL. 64

2010

  1. Influence of IL2RA rs2104286 polymorphism in the risk of biopsy-proven giant cell arteritis

    Journal of Rheumatology, Vol. 37, Núm. 11, pp. 2331-2333